Exact Sciences Intrinsic Value Calculator – Exact Sciences to Release Quarterly Earnings on Wednesday

🌥️Trending News

Exact Sciences ($NASDAQ:EXAS) is a leading biotechnology company focused on developing innovative solutions for early detection and prevention of some of the world’s most deadly diseases. On Wednesday, the company will announce its quarterly earnings results. This is an important milestone for investors, as the results are likely to provide insight into the company’s financial performance and future prospects. The results of Exact Sciences’ quarterly earnings report can have a significant impact on the stock price of the company. As a result, investors will be closely monitoring the earnings release. Analysts will provide their opinions on the company’s performance, which can help investors better understand the potential for growth.

Additionally, investors will be looking for indications of future performance and any potential risks associated with the company. Overall, this earnings release is an important indicator of Exact Sciences’ financial performance and investor sentiment. Analysts are expecting strong results, and investors are eager to see if the company will meet or exceed those expectations. With the stock price having risen steadily over the past year, many believe that this quarterly release will be a positive one for Exact Sciences and its shareholders.

Earnings

EXACT SCIENCES, a renowned provider of healthcare solutions, is set to release their quarterly earning report on Wednesday. According to the report, the company generated a total revenue of 434.82M USD in the fiscal year 2023 Q2 as of June 30 2021.

However, this income was not enough to recoup the losses that the company faced and resulted in a net income loss of 176.91M USD. This figure showed a 16.6% decrease in total revenue compared to the previous year. It should also be noted that the company experienced an increase of total revenue from 434.82M USD to 622.09M USD in the last 3 years. Investors and stakeholders are now awaiting the information that will be revealed in EXACT SCIENCES’s upcoming financial report to assess the impact of these figures on the company’s performance.

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Exact Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Exact Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Exact Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Exact Sciences are shown below. More…

Share Price

Exact Sciences, an American molecular diagnostics company, is set to release their quarterly earnings on Wednesday. Prior to this announcement, the company’s stock opened at $65.0, dropped 6.0% from the previous closing price of 65.8, and closed at $61.8. Investors are now eagerly awaiting the release of Exact Sciences’ quarterly earnings to see if the company can keep up its current trajectory and continue to experience positive growth. Live Quote…

Analysis – Exact Sciences Intrinsic Value Calculator

At GoodWhale, we conducted an analysis of EXACT SCIENCES‘s wellbeing and found that its fair value is around $99.8, as calculated by our proprietary Valuation Line. Despite this, EXACT SCIENCES stock is currently being traded at $61.8, representing a 38.1% discount to its fair value. This presents an attractive investment opportunity for those looking to add the stock to their portfolio. We believe that by investing in EXACT SCIENCES now, investors can benefit from significant upside potential in the long-term. More…

Peers

The market for cancer diagnostics is highly competitive. Exact Sciences Corp, Inoviq Ltd, Myriad Genetics Inc, and BCAL Diagnostics Ltd are all major players in the industry. Each company has its own unique strengths and weaknesses, and the competition between them is fierce.

– Inoviq Ltd ($ASX:IIQ)

Inoviq Ltd has a market cap of 55.21M as of 2022. The company’s Return on Equity for the same year is -13.68%.

Inoviq Ltd is a technology company that focuses on developing innovative solutions for the mobile communications industry. The company’s products and services are designed to improve the efficiency and productivity of mobile operators and enterprises. Inoviq Ltd’s portfolio includes a wide range of products and services, such as mobile network optimization, mobile device management, and mobile application development.

– Myriad Genetics Inc ($NASDAQ:MYGN)

Myriad Genetics Incorporated is a biotechnology company that focuses on the development and commercialization of molecular diagnostic tests. The company’s tests are used for the early detection and risk assessment of various diseases, including cancer, cardiovascular disease, and Alzheimer’s disease. Myriad Genetics Incorporated is headquartered in Salt Lake City, Utah.

Summary

Exact Sciences is set to announce their earnings for the quarter on Wednesday. Investing analysis of this company may be of interest to potential investors. The stock price of Exact Sciences has moved down in the same day as the announcement of its earnings, which could be an indication of what to expect from the company’s financial results. Analysts will be closely watching the company’s revenue, expenses, profitability, and other key financial metrics in order to determine if Exact Sciences is a viable long-term investment.

Additionally, investors should take into account the company’s competitive position in its industry, recent performance, and macroeconomic factors that may affect its short-term outlook. By taking all of these factors into consideration, investors can make an educated decision on whether or not they should invest in Exact Sciences.